# The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients

> **NCT07138755** · PHASE2 · RECRUITING · sponsor: **The Third Xiangya Hospital of Central South University** · enrollment: 35 (estimated)

## Conditions studied

- NSCLC
- Sintilimab
- Adaptive Radiotherapy

## Interventions

- **DRUG:** Experimental

## Key facts

- **NCT ID:** NCT07138755
- **Lead sponsor:** The Third Xiangya Hospital of Central South University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-29
- **Primary completion:** 2028-12
- **Final completion:** 2030-09
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07138755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07138755, "The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07138755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*